The Case for More Aggressive Masking in Psychedelic Trials

.

In this viewpoint paper, the authors' main argument is that inadequate masking is a major methodological problem in high-dose psychedelic research and that researchers should investigate substantially more aggressive approaches to masking.

Yang et al. argue that inadequate masking represents a major methodological challenge in high-dose psychedelic trials. They note that more than 90% of participants in such trials can correctly identify their treatment allocation, substantially exceeding the approximate 60% reported in antidepressant trials.

The authors argue that this degree of unmasking may allow treatment expectations and beliefs to contribute to observed outcomes, thereby complicating the estimation of pharmacologically specific effects. They propose UMBRAA (unidentifiable multidrug blinding with reduced, authorized awareness), a framework combining multidrug active comparators from distinct pharmacological classes with authorized incomplete disclosure of aspects of the trial design.

The proposed comparator would aim to produce an intense but unfamiliar altered state while avoiding psilocybin's primary 5-HT2A mechanism and minimizing independent therapeutic effects. The authors acknowledge substantial safety and ethical concerns and emphasize that UMBRAA is a proposed methodological strategy requiring empirical investigation, rather than a validated approach to masking psychedelic trials.

Yang KH, Heifets BD, Krystal A, Woolley JD. The Case for More Aggressive Masking in Psychedelic Trials. JAMA Psychiatry. 2026 Sep 16. doi: 10.1001/jamapsychiatry.2026.2858. Epub ahead of print. PMID: 42747812. Read Paper

For more psychedelic news and research, visit the psychedelic health professional network homepage.